Zydus Lifesciences Q3 Results FY2023, PAT at Rs. 6229 million

Zydus Lifesciences Q3 Results FY2023

by Shreya Anaokar Last Updated: Feb 06, 2023 - 04:45 pm 1.1k Views

On 3rd February,  Zydus Lifesciences announced its results for the third quarter of FY2023.

Key Highlights:

- Revenue from Operations at Rs. 43,623 million, up 20% over last year. 
- Research & Development (R&D) investments for the quarter stood at Rs. 3,435 million (7.9% of revenues). 
- EBITDA for the quarter was Rs. 9,560 million, up 27% yoy. EBITDA margin for the quarter was 21.9% against 20.6% in Q3 FY22. 
- Net Profit for the quarter was Rs. 6,229 million, up 24% yoy. 

Business Highlights:

- The Indian business registered revenues of Rs. 16,436 million, up by 13% yoy. 
- The formulation business, registered revenues of Rs. 12,316 million, up by 14% yoy.
- Consumer Wellness business registered revenues of Rs. 4,120 million, up by 8 % yoy
- US formulations business registered revenues of Rs. 19,250 million, up by 29% yoy 
- Emerging Markets (EM) formulations business continued to deliver double digit growth as it registered revenues of Rs. 3,078 million, up 15% yoy.
- Europe formulations business registered revenues of Rs. 705 million, up by 4% yoy.
- API business registered revenues of Rs. 1,881 million, up 14% yoy.
- Alliances & Others registered revenues of Rs. 248 million, down 55% yoy.

Commenting on the results, Dr. Sharvil Patel, Managing Director - Zydus Lifesciences Limited said: “We are pleased with our Q3 FY23 performance showcasing robust growth across key businesses and improved profitability. With India Formulations in a double-digit growth trajectory and US business continuing to build traction, portfolio execution will sustain growth momentum. We aim to enhance profitability steadily going ahead while remaining committed to build long term growth levers. Our commitment to maintaining high quality standards and an agile supply chain positions us well to capitalize on our R&D pipeline and advance our innovation efforts.”

How do you rate this article?

Fill in your details below:

Start Investing in 5 mins*

Rs. 20 Flat Per Order | 0% Brokerage

About the Author

Shreya Anaokar is a Content Writer at 5paisa. She has completed her Master’s in Finance and Graduation in Statistics from the University of Mumbai. 


Investment/Trading is subject to market risk, past performance doesn’t guarantee future performance. The risk of trading/investment loss in securities markets can be substantial. Also, the above report is compiled from data available on public platforms.

Open Free Demat Account

Resend OTP
Please Enter OTP
Account belongs to

By proceeding, you agree to the T&C.

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number